These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10801249)

  • 61. Methylnaltrexone in the treatment of opioid-induced constipation.
    Greenwood-Van Meerveld B; Standifer KM
    Clin Exp Gastroenterol; 2008; 1():49-58. PubMed ID: 21677823
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gut motility and transit changes in patients receiving long-term methadone maintenance.
    Yuan CS; Foss JF; O'Connor M; Moss J; Roizen MF
    J Clin Pharmacol; 1998 Oct; 38(10):931-5. PubMed ID: 9807974
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Methylnaltrexone: reversing the gastrointestinal effects of opioids.
    Rosow CE
    Anesthesiology; 1997 Oct; 87(4):736-7. PubMed ID: 9357871
    [No Abstract]   [Full Text] [Related]  

  • 64. Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation.
    Lin DH; Wang CZ; Qin LF; Xie XX; Wang JT; Gu M; McEntee E; Yuan CS
    Drug Dev Ind Pharm; 2014 Feb; 40(2):186-91. PubMed ID: 23327357
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of orocaecal transit times assessed by the lactulose/breath hydrogen and the sulphasalazine/sulphapyridine methods.
    Staniforth DH
    Gut; 1989 Jul; 30(7):978-82. PubMed ID: 2569435
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Methylnaltrexone potentiates body weight and fat reduction with leptin.
    Yuan CS; Sun S; Attele A; Wang CZ; Tong R; Israel RJ
    J Opioid Manag; 2009; 5(6):373-8. PubMed ID: 20073411
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of morphine and liposomal morphine in a model of intestinal inflammation in mice.
    Pol O; Planas E; Puig MM
    Pharmacology; 1996 Sep; 53(3):180-9. PubMed ID: 8931103
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Central pharmacological activity of a quaternary ammonium compound in streptozotocin diabetic mice.
    Quock RM; Ishii MM; Emmanouil DE
    Life Sci; 1988; 43(17):1411-7. PubMed ID: 2846978
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Involvement of substance P and central opioid receptors in morphine modulation of the CHS response.
    Nelson CJ; Lysle DT
    J Neuroimmunol; 2001 Apr; 115(1-2):101-10. PubMed ID: 11282159
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The analgesic tramadol has minimal effect on gastrointestinal motor function.
    Wilder-Smith CH; Bettiga A
    Br J Clin Pharmacol; 1997 Jan; 43(1):71-5. PubMed ID: 9056055
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oral naloxone antagonizes loperamide-induced delay of orocecal transit.
    Basilisco G; Camboni G; Bozzani A; Paravicini M; Bianchi PA
    Dig Dis Sci; 1987 Aug; 32(8):829-32. PubMed ID: 3608730
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Methylnaltrexone to Reduce the Inhibitory Effects of Opioids on Drug Absorption.
    Schoergenhofer C; Jilma B
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1550-1552. PubMed ID: 31377266
    [No Abstract]   [Full Text] [Related]  

  • 73. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon.
    Roda A; Simoni P; Magliulo M; Nanni P; Baraldini M; Roda G; Roda E
    World J Gastroenterol; 2007 Feb; 13(7):1079-84. PubMed ID: 17373743
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea.
    Washington N; Ridley P; Thomas C; Spiller RC; Watts PJ; Wilson CG
    Aliment Pharmacol Ther; 1998 Jun; 12(6):583-8. PubMed ID: 9678820
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Idiopathic slow-transit constipation: whole gut transit times, measured by a new simplified method, are not shortened by opioid antagonists.
    Fotherby KJ; Hunter JO
    Aliment Pharmacol Ther; 1987 Aug; 1(4):331-8. PubMed ID: 2979677
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Methylnaltrexone for Opioid-Induced Dysmotility in Critically Ill Infants and Children: A Pilot Study.
    Smith CJ; Sierra CM; Robbins J; Chang NY; Mirza F
    J Pediatr Pharmacol Ther; 2023; 28(2):136-142. PubMed ID: 37139255
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of vection-induced motion sickness on gastric myoelectric activity and oral-cecal transit time.
    Muth ER; Stern RM; Koch KL
    Dig Dis Sci; 1996 Feb; 41(2):330-4. PubMed ID: 8601378
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Quantitative, noninvasive assessment of antidiarrheal actions of codeine using an experimental model of diarrhea in man.
    Barrow L; Steed KP; Spiller RC; Maskell NA; Brown JK; Watts PJ; Melia CD; Davies MC; Wilson CG
    Dig Dis Sci; 1993 Jun; 38(6):996-1003. PubMed ID: 8389688
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Slowing of intestinal transit by fat depends on naloxone-blockable efferent, opioid pathway.
    Zhao XT; Wang L; Lin HC
    Am J Physiol Gastrointest Liver Physiol; 2000 Jun; 278(6):G866-70. PubMed ID: 10859215
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Single doses of ritodrine delay orocaecal transit in patients with irritable bowel syndrome.
    Basilisco G; Camboni MG; Bozzani A; Molgora M; Bianchi PA
    Br J Clin Pharmacol; 1990 Mar; 29(3):355-8. PubMed ID: 2310659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.